๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Crohn's Disease

Stopping PPI Therapy in Inactive IBD NCT07691138Phase 41 site๐Ÿ“ Nottingham University of Nottingham ยท Tests: Continue PPI Therapy, Withdraw PPI Therapy Impact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease NCT06719778NA1 site๐Ÿ“ Bamberg Universitรคt Duisburg-Essen ยท Tests: Two-stage nutritional therapy concept Treatment of Moderate to Severe Refractory Crohn's Disease NCT06721962Phase 1, Phase 213 sites๐Ÿ“ Scottsdale๐Ÿ“ Sacramento๐Ÿ“ San Francisco Tr1X, Inc. ยท Tests: TRX103, Cyclophosphamide A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease NCT06221254NA4 sites๐Ÿ“ Beersheba๐Ÿ“ Haifa๐Ÿ“ Petah Tikva Soroka University Medical Center ยท Tests: COBMINDEX digital application, Human therapist (Control) Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study NCT06896305NA1 site๐Ÿ“ Milan IRCCS Ospedale San Raffaele ยท Tests: CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapy, Anti-TNF Therapy Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease NCT06274554Phase 31 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Fluconazole, Placebo, IL-23 Therapy Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease NCT07078994Phase 220 sites๐Ÿ“ Barnaul๐Ÿ“ Ufa๐Ÿ“ Moscow Biocad ยท Tests: anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, higโ€ฆ HB-adMSCs for the Treatment of Crohn's Disease NCT07077746Phase 21 site๐Ÿ“ Sugar Land Hope Biosciences Research Foundation ยท Tests: HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1) NCT05903066n/a18 sites๐Ÿ“ Liรจge๐Ÿ“ Amiens๐Ÿ“ Bordeaux Groupe d'Etude Therapeutique des Affections Inflammatoires โ€ฆ ยท Tests: Magnetic Resonance Enterography (MRE) Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD NCT06997965Phase 48 sites๐Ÿ“ Miami๐Ÿ“ Orlando๐Ÿ“ Chicago Alimentiv Inc. ยท Tests: Mirikizumab A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab NCT07532213n/a1 site๐Ÿ“ Bern Janssen-Cilag A.G., Switzerland IBD Strong Peer2Peer for Self-Management of Psychological Distress NCT05722236NA1 site๐Ÿ“ Halifax Jennifer Jones ยท Tests: IBD Strong Peer2Peer, Waitlist control Microencapsulated Sodium Propionate in IBD Microbiota Modulation NCT07883044NA1 site๐Ÿ“ Padova University of Padova ยท Tests: Microencapsulated sodium propiolate, Microencapsulated sodium Butyrate Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease NCT06976853Phase 23 sites๐Ÿ“ Beverly Hills๐Ÿ“ St Louis๐Ÿ“ New York Washington University School of Medicine ยท Tests: Tirzepatide, Standard of care treatment Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease NCT06925061Phase 212 sites๐Ÿ“ Clermont-Ferrand๐Ÿ“ Crรฉteil๐Ÿ“ Le Kremlin-Bicรชtre Madeleine Bezault ยท Tests: After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with โ€ฆ Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease NCT06902987Phase 11 site๐Ÿ“ Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University ยท Tests: Upadacitinib A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies NCT06890637NA6 sites๐Ÿ“ Kochi๐Ÿ“ Mumbai๐Ÿ“ New Delhi All India Institute of Medical Sciences ยท Tests: Fecal Microbial Transplantation, Crohns Disease Exclusion Diet, Sham transplantation, Sham Diet, Advanced therapy Risankizumab in Children With Crohn's Disease (RisaKids) NCT06298188NA1 site๐Ÿ“ Jerusalem Shaare Zedek Medical Center ยท Tests: Risankizumab Standardized Microbiota Transplant Therapy in Crohn's Disease NCT06631586Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ New York๐Ÿ“ Dallas University of Minnesota ยท Tests: MTP-101C, MTP-101S A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) NCT06430801Phase 3499 sites๐Ÿ“ Dothan๐Ÿ“ Phoenix๐Ÿ“ Sun City Merck Sharp & Dohme LLC ยท Tests: IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo Lesion Size Measurement During Gastrointestinal Endoscopies NCT07770425n/a1 site๐Ÿ“ Montreal Centre hospitalier de l'Universitรฉ de Montrรฉal (CHUM) STUDY OF THE ADDED VALUE OF A TRANSMURAL EVALUATION IN PATIENTS WITH CROHN'S DISEASE UNDER BIOTHERAPY WITH CLOSE FECAL CALPROTECTIN FOLLOW-UP NCT04973423NA17 sites๐Ÿ“ Amiens๐Ÿ“ Aurillac๐Ÿ“ Bayonne University Hospital, Clermont-Ferrand ยท Tests: MRI Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. NCT06180382Phase 412 sites๐Ÿ“ Le Kremlin-Bicรชtre๐Ÿ“ Amiens๐Ÿ“ Lille Centre Hospitalier Universitaire de Saint Etienne ยท Tests: Adalimumab, Vedolizumab Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE) NCT06315179n/a1 site๐Ÿ“ Seattle Seattle Children's Hospital ยท Tests: Esophagogastroduodenoscopy (EGD) with biopsy, Colonoscopy w/ biopsy Leucine-rich ฮฑ2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context NCT07621783n/a1 site๐Ÿ“ Bonheiden Imelda GI Clinical Research Center ยท Tests: Leucine-rich ฮฑ2-glycoprotein Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease NCT07456566NA1 site๐Ÿ“ Ann Arbor University of Michigan ยท Tests: Digital self-management program, Standard Care Real-World Study of IL-23 Inhibitors in Active Crohn's Disease NCT07545317n/a1 site๐Ÿ“ Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University ยท Tests: IL-23 inhibitor, TNF inhibitors Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD NCT06064864NA1 site๐Ÿ“ Seoul Asan Medical Center ยท Tests: Infliximab-Dyyb Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease NCT06520397Phase 41 site๐Ÿ“ Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University ยท Tests: Ustekinumab and Upadacitinib, Ustekinumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy